Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo's hidden toll: brain changes decades after childhood bone cancer

NCT ID NCT05071001

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 92 adults who had chemotherapy for bone tumors (osteosarcoma or Ewing sarcoma) as children or teenagers. Researchers used surveys to measure thinking, memory, and concentration problems years after treatment. The goal was to understand which patients are most at risk for long-term brain side effects, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

92 people

The number who actually took part.

Started

Mar 2021

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For study OSE A and B * Patients treated for a bone sarcoma: Ewing or osteosarcoma * Age under 19 years at initial diagnosis * Treated in the Pediatric Oncology Department of Gustave For patients diagnosed between 01.01.2001 and 31.12.2010: patients alive in complete remission at least 5 years after diagnosis * Treated with at least one course of HDMTX for osteosarcoma * Treated without HDMTX for Ewing sarcoma * Time interval between the end of treatment and inclusion \>10 y * Age \> 21 y at inclusion * Patients with informed consent signed * Patient under guardianship * Affiliated to French health insurance or beneficiary of the same or equivalent For study OSE- B only: * Treated with at least 8 courses of HDMTX for osteosarcoma * Treated without HDMTX for Ewing sarcoma * Patients with Ewing sarcoma will have to be matched with osteosarcoma patients according to age at the time of treatment, sex, and duration of follow-up * School level equivalent of at least the end of primary school Exclusion Criteria: For study OSE A and B * Brain radiotherapy * Previous relapse except those treated by local treatment without any chemotherapy * Second malignancy treated with chemotherapy * High dose chemotherapy with stem cell support * Non-French speaking patients * Pregnant and breastfeeding women For study OSE- B only: \- Patient deprived of his liberty by a judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adults treated during childhood or adolescence for A malignant bone tumor (osteosarcoma and Ewing sarcoma) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adults treated during childhood or adolescence for A malignant bone tumor (osteosarcoma and Ewing sarcoma)

Contacts and locations

Locations

  • Gustave Roussy

    Villejuif, 94800, France